TP53 and neoplasm: In addition, identifying circulating tumor DNA using the molecular detection of APC, KRAS, and p53 gene mutations is a potential tool for the early detection of postoperative recurrence and metastases, which may be correlated with poor clinical outcomes in CRC patients 6.